新宝丸通过调节LAD诱导的慢性心力衰竭小鼠的CaSR/AQP2通路来减弱水分保留
Shiqi Li1, Yuanping Wang1,2, Xulan Cui3
1Shunde Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Foshan, Guangdong, 528333, China.
Journal of traditional and complementary medicine
|September 22, 2025
概括
新宝药 (XBP) 通过通过CaSR/p38-MAPK和CaSR/CREB通路调节水素-2 (AQP2) 表达,有效地管理慢性心力衰竭 (CHF) 的水. 这改善了心脏功能,并减少了流体过载.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 保持水分是慢性心力衰竭 (CHF) 发展和恶化的关键因素.
- 新宝丸 (XBP) 是一种常见的治疗心脏不全症的辅助疗法,但其对保持水分的具体影响尚未完全理解.
研究的目的:
- 为了研究XBP在CHF的老鼠模型中对保持水分的治疗效果.
- 阐明XBP影响CHF水平衡的潜在分子机制.
主要方法:
- 在Sprague-Dawley大鼠中通过LAD动脉绑定建立了一个慢性心力衰竭 (CHF) 模型.
- 评估了心脏功能,心脏重塑和纤维化. 用各种分子技术分析 CaSR/AQP2信号通路的表达.
- 用一个CaSR抑制剂 (NPS2143) 来验证CaSR的作用.
主要成果:
- 施用XBP改善了心脏喷射分数和分数缩短,并在CHF大鼠中减少了心脏纤维化.
- XBP显著增加了24小时的尿量,并降低了尿蛋白水平.
- 通过对CaSR和p-p38-MAPK进行上调,XBP降低了内水素-2 (AQP2) 表达的调节,促进了AQP2的无化,并抑制了p-CREB以抑制AQP2的转录.
结论:
- 通过调节脏AQP2表达,XBP改善了CHF中的水,通过双路径调节AQP2表达:CaSR/p38-MAPK介导的全方位化和CaSR/CREB介导的转录.
- 这些发现强调了XBP作为治疗慢性心力衰竭中管理液体平衡的潜在治疗剂.
相关概念视频
01:22Heart Failure Drugs: Diuretics
809
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
809
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
942
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.3K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.3K
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.5K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.5K
01:30Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
01:29Heart Failure II: Pathophysiology
734
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
734